Chronic Inflammatory Demyelinating Polyradiculoneuropathy
29
9
10
12
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 29/100
6.9%
2 terminated out of 29 trials
85.7%
-0.8% vs benchmark
28%
8 trials in Phase 3/4
50%
6 of 12 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 12 completed trials
Clinical Trials (29)
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
Clinical Trial to Assess the Safety of a Novel Scaffold Biomaterial
Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
Do IgG Level Variations in CIDP and MMN Patients Following Initial Intravenous IVIg Treatment Correlate With Ultimate Dosing
Tongji NADs Cohort
Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in Patients With r/r Neurological Autoimmune Diseases
Proof-of-concept Study for SAR445088 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Our Study Aims to Determine if Nerve Alterations in Acute GBS and CIDP Detectable by Ultrasound Match Electrodiagnostic Findings and if This Method Aids Early Diagnosis, Predict Their Outcomes and Differentiate Between Axonal and Demyelinating Subtypes.
Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases
Role of High Frequency Ultrasound in Demyelinating Polyneuropathies
Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System.
Biomarkers in Autoimmune Disease of Nervous System
Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP
Evaluation of the Diagnostic Contributions of Nerve Ultrasound in Chronic Inflammatory Demyelinating Polyneuropathy Associating Systemic Diseases (CIDP Echo-nerf)
Genetic Architecture of Chronic Inflammatory Demyelinating Polyradiculoneuropathy
A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Exploratory Study of Predictive Markers of the Therapeutic Response in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Treated With Intravenous Immunoglobulin
InertiaLocoGraphy as a Biomarker of Immunoglobulin Therapy Efficacy in Chronic Inflammatory Demyelinating Polyradiculoneuropathy